OmniAb Raises 2026 Guidance After Q1 Beat, But Cash Burn and Revenue Lumpiness Persist

What happened

OmniAb reported Q1 2026 results with 'strong momentum,' citing partnered program advances and raised its 2026 revenue guidance. The company highlighted multiple programs moving into later-stage clinical development, supporting the narrative of platform value. However, the raised guidance comes from a low base; the DeepValue Master Report flagged 2026 revenue of $25M–$30M as a key checkpoint, and Q1 results need to show sustained conversion of program counts into recognizable milestone revenue. The cash burn trajectory remains critical, with year-end cash targeted at $30M–$35M, and any sign of ATM usage would be a thesis breaker.

Implication

Investors should view the raised guidance as a necessary but insufficient condition for a bullish thesis. The stock still trades below tangible book value, reflecting market skepticism about revenue durability. The immediate implication is that management is signaling confidence in partner milestones and cost control, but the Q1 2026 earnings call must provide granularity: (1) the composition of the revenue beat (license vs. milestone vs. xPloration), (2) disclosed xPloration install metrics, and (3) reaffirmation of the $50M–$55M non-GAAP cash cost guidance. If these are missing, the guidance raise could be a head fake before a financing event. The critical catalysts remain H1 2026 partner clinical updates (Merck KGaA M9140 Phase III start, Immunovant batoclimab topline) and xPloration scaling. Absent evidence of these, the stock remains a show-me story with downside risk to $1.10 if milestones slip.

Thesis delta

The raised 2026 guidance incrementally supports the base case (implied value $2.10) but does not yet validate the bull case ($3.20) because it does not address the core uncertainty: whether xPloration can scale beyond a single instrument sale or whether partner milestones will materialize on time. The guidance raise reduces but does not eliminate the probability of the bear case; the 90-day checkpoint on xPloration conversion and partner catalyst integrity now carries even more weight. If the Q2 2026 results show xPloration revenue below $1.0M or no milestone disclosures, the stock could re-test its lows.